Navdeep Boparai
Overview
Explore the profile of Navdeep Boparai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
2214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boparai N, Girgis M, Kiamanesh O, Al-Arnawoot A, Amad H, Tsang W
CASE (Phila)
. 2021 Mar;
5(1):62-66.
PMID: 33644516
No abstract available.
2.
Safadi R, Noviello S, Boparai N, McPhee F
Clin Case Rep
. 2016 Jul;
4(7):653-6.
PMID: 27386121
There is currently minimal clinical experience regarding retreatment options for patients failing direct-acting antiviral combination regimens. Here, we report the outcomes of a HCV genotype 1b-infected patient with virologic failure...
3.
Zeuzem S, Hezode C, Bronowicki J, Loustaud-Ratti V, Gea F, Buti M, et al.
J Hepatol
. 2015 Oct;
64(2):292-300.
PMID: 26453968
Background & Aims: We evaluated the combination of daclatasvir (pan-genotypic NS5A inhibitor) and simeprevir (NS3/4A protease inhibitor), with or without ribavirin, in hepatitis C virus genotype 1-infected patients. Methods: This...
4.
Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Brau N, et al.
JAMA
. 2015 May;
313(17):1728-35.
PMID: 25942723
Importance: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. Objective: To determine the rates of sustained virologic response...
5.
Poynard T, Bruix J, Schiff E, Diago M, Berg T, Moreno-Otero R, et al.
J Hepatol
. 2012 Nov;
58(3):452-9.
PMID: 23159770
Background & Aims: Therapeutic options for patients failing hepatitis C retreatment are limited. EPIC(3) included a prospective trial assessing long-term peginterferon alfa-2b (PegIFNα-2b) maintenance therapy in patients with METAVIR fibrosis...
6.
Poordad F, Bronowicki J, Gordon S, Zeuzem S, Jacobson I, Sulkowski M, et al.
Gastroenterology
. 2012 May;
143(3):608-618.e5.
PMID: 22626609
Background & Aims: Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods: Previously...
7.
Jacobson I, Marcellin P, Zeuzem S, Sulkowski M, Esteban R, Poordad F, et al.
Hepatology
. 2012 May;
56(2):567-75.
PMID: 22619063
Unlabelled: In comparison with peginterferon/ribavirin alone, boceprevir with peginterferon/ribavirin significantly improves sustained virological response (SVR) rates in patients with chronic hepatitis C virus (HCV) genotype 1 infections, but treatment failure...
8.
Melia M, Muir A, McCone J, Shiffman M, King J, Herrine S, et al.
Hepatology
. 2011 Apr;
54(1):70-8.
PMID: 21488082
Unlabelled: Black Americans are disproportionally infected with hepatitis C virus (HCV) and are less likely than whites to respond to treatment with peginterferon (PEG-IFN) plus ribavirin (RBV). The impact of...
9.
Bacon B, Gordon S, Lawitz E, Marcellin P, Vierling J, Zeuzem S, et al.
N Engl J Med
. 2011 Apr;
364(13):1207-17.
PMID: 21449784
Background: In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal. Boceprevir,...
10.
Poordad F, McCone Jr J, Bacon B, Bruno S, Manns M, Sulkowski M, et al.
N Engl J Med
. 2011 Apr;
364(13):1195-206.
PMID: 21449783
Background: Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of...